{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T17:58:39Z","timestamp":1773251919370,"version":"3.50.1"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"3-4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Human Papillomavirus (HPV) is the most common sexually transmitted infection globally, with millions of new cases reported each year. Human Papillomavirus is associated with cervical, anal, vulva, penile, and esophageal cancer. Cervical cancer is a significant threat to women because of its insidious nature; thus, cervical cancer screening remains crucial for early detection and intervention.<\/jats:p>\n                    <jats:p>The most effective method to protect against HPV-related cancers is through vaccination with the HPV vaccine. The Human Papillomavirus vaccine targets the most common high-risk HPV strains. Vaccination is recommended for both males and females between the ages of 9-26. Vaccination reduces the risk of infection and contributes to the prevention of HPV-related cancers, representing a crucial public health initiative in battling HPV. The active duty military population has low HPV vaccination rates. A visit for a pap smear, the screening for cervical cancer, is an optimal time for providers to discuss the HPV vaccine. This research aims to understand the low HPV vaccination rate among active duty women and whether providers are maximizing opportunities to promote vaccination against HPV.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>A retrospective medical chart review was performed at a single military treatment facility (MTF) of active duty women between the ages of 21-26, who had an abnormal pap smear, and no record of receiving the HPV vaccine. A chart review was conducted for the visit in which the pap smear was performed, as well as the follow-up visit\/phone call to discuss the abnormal pap smear results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Seven hundred fifty-one charts were reviewed from 2005 to 2021 of unvaccinated active duty women with an abnormal pap smear. 46.3% of the abnormal pap smears were low-grade squamous intraepithelial cells (LGSIL), whereas 3.3% were high-grade squamous intraepithelial cells (HGSIL). Of the charts reviewed, 8.3% of the patients noted they had been vaccinated; 13.8% of the charts had documented recommendations for the HPV vaccination; and 77.9% had no documentation regarding the patient\u2019s HPV status or recommendation for vaccination.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Although the HPV vaccine is effective in reducing the risk of HPV-related cancers, our results indicate the need for increased awareness and education practices amongst providers in promoting the HPV vaccine.<\/jats:p>\n                    <jats:p>A limitation of the study was that it was conducted at a single MTF. The study was not able to distinguish between provider types or clinic settings. Possible proposals for future studies include evaluating why the HPV vaccination rates amongst the active duty population are low. Pap smears are a prime opportunity for providers to engage in discussion of the importance of the HPV vaccine and encourage adherence.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/milmed\/usaf404","type":"journal-article","created":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T11:36:24Z","timestamp":1753788984000},"page":"e508-e512","source":"Crossref","is-referenced-by-count":0,"title":["Recommendation for Human Papillomavirus Vaccine after Abnormal Pap Smear in Unvaccinated Active Duty Women"],"prefix":"10.1093","volume":"191","author":[{"given":"Capt Eleanor","family":"Stout","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Naval Medical Center Portsmouth , Portsmouth, VA 23708,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L T Hannah","family":"Poiani","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Naval Medical Center Portsmouth , Portsmouth, VA 23708,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Mcglynn","sequence":"additional","affiliation":[{"name":"Clinical Investigation Department, Naval Medical Center Portsmouth , Portsmouth, VA 23708,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8817-5002","authenticated-orcid":false,"given":"C D R Sharon C","family":"Enujioke","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Naval Medical Center Portsmouth , Portsmouth, VA 23708,","place":["United States"]},{"name":"Department of Pediatrics, Uniformed Services University of the Health Sciences , Bethesda, MD 20814,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,8,8]]},"reference":[{"key":"2026031018415614500_usaf404-B1","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.idc.2013.09.001","article-title":"HPV and HPV-associated diseases","volume":"27","author":"Dunne","year":"2013","journal-title":"Infect Dis Clin North Am"},{"key":"2026031018415614500_usaf404-B2","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1080\/14760584.2022.2125383","article-title":"HPV vaccine introduction in the Americas: a decade of progress and lessons learned","volume":"21","author":"De Oliveira","year":"2022","journal-title":"Expert Rev Vaccines"},{"key":"2026031018415614500_usaf404-B3","first-page":"289","article-title":"Sexually transmitted human papillomavirus: update in epidemiology, prevention, and management","volume":"37","author":"Plotzker","year":"2023","journal-title":"Infect Dis Clin"},{"key":"2026031018415614500_usaf404-B4","author":"Centers for Disease Control and Prevention"},{"key":"2026031018415614500_usaf404-B5","doi-asserted-by":"crossref","first-page":"e28208","DOI":"10.1002\/jmv.28208","article-title":"The association between human papillomavirus and bladder cancer: evidence from meta-analysis and two-sample Mendelian randomization","volume":"95","author":"Sun","year":"2023","journal-title":"J Med Virol"},{"key":"2026031018415614500_usaf404-B6","doi-asserted-by":"crossref","first-page":"105155","DOI":"10.1016\/j.ebiom.2024.105155","article-title":"Human papillomavirus infection and the risk of cancer at specific sites other than anogenital tract and oropharyngeal region: an umbrella review","volume":"104","author":"Cao","year":"2024","journal-title":"EBioMedicine"},{"key":"2026031018415614500_usaf404-B7","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1001\/jama.2023.13174","article-title":"Cervical cancer screening: a review","volume":"330","author":"Perkins","year":"2023","journal-title":"JAMA"},{"key":"2026031018415614500_usaf404-B8","doi-asserted-by":"crossref","first-page":"e1115","DOI":"10.1016\/S2214-109X(22)00241-8","article-title":"Cervical cancer screening programmes and age-specific coverage estimates for 202 countries and territories worldwide: a review and synthetic analysis","volume":"10","author":"Bruni","year":"2022","journal-title":"Lancet Global Health"},{"key":"2026031018415614500_usaf404-B9","doi-asserted-by":"crossref","first-page":"106400","DOI":"10.1016\/j.ypmed.2020.106400","article-title":"Cervical cancer screening in the United States: challenges and potential solutions for underscreened groups","volume":"144","author":"Fuzzell","year":"2021","journal-title":"Prev Med"},{"key":"2026031018415614500_usaf404-B10","author":"The American College of Obstetricians and Gynecologists"},{"key":"2026031018415614500_usaf404-B11","author":"US Preventive Services Task Force"},{"key":"2026031018415614500_usaf404-B12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/ijgc-2021-003014","article-title":"Human papillomavirus-independent cervical cancer","volume":"32","author":"Fernandes","year":"2022","journal-title":"Int J Gynecol Cancer"},{"key":"2026031018415614500_usaf404-B13","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3390\/diagnostics13020243","article-title":"Updates on HPV vaccination","volume":"13","author":"Illah","year":"2023","journal-title":"Diagnostics"},{"key":"2026031018415614500_usaf404-B14","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41541-023-00628-8","article-title":"Differences in HPV-specific antibody Fc-effector functions following Gardasil\u00ae and Cervarix\u00ae vaccination","volume":"8","author":"Roy","year":"2023","journal-title":"NPJ Vaccines"},{"key":"2026031018415614500_usaf404-B15","doi-asserted-by":"crossref","first-page":"e2022056597","DOI":"10.1542\/peds.2022-056597","article-title":"Human papillomavirus vaccination trends among adolescents: 2015 to 2020","volume":"150","author":"Lu","year":"2022","journal-title":"Pediatrics"},{"key":"2026031018415614500_usaf404-B16","doi-asserted-by":"crossref","first-page":"EVIDoa2100056","DOI":"10.1056\/EVIDoa2100056","article-title":"Efficacy of single-dose HPV vaccination among young African women. Efficacy of single-dose HPV vaccination among young African women","volume":"1","author":"Barnabas","year":"2022","journal-title":"NEJM Evid"},{"key":"2026031018415614500_usaf404-B17","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/978-3-030-57362-1_8","volume-title":"Viruses and Human Cancer: From Basic Science to Clinical Prevention","author":"Farmer","year":"2021"},{"key":"2026031018415614500_usaf404-B18","doi-asserted-by":"crossref","first-page":"e052016","DOI":"10.1136\/bmjopen-2021-052016","article-title":"Estimate of global human papillomavirus vaccination coverage: analysis of country-level indicators","volume":"11","author":"Spayne","year":"2021","journal-title":"BMJ Open."},{"key":"2026031018415614500_usaf404-B19","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.vaccine.2018.02.007","article-title":"Improving human papillomavirus vaccination rates throughout military treatment facilities","volume":"36","author":"Dawson","year":"2018","journal-title":"Vaccine"},{"key":"2026031018415614500_usaf404-B20","doi-asserted-by":"crossref","first-page":"e1926","DOI":"10.1093\/milmed\/usab562","article-title":"Factors associated with human papillomavirus vaccine initiation and compliance among US military service members","volume":"188","author":"Matsuno","year":"2023","journal-title":"Mil Med"},{"key":"2026031018415614500_usaf404-B21","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/milmed\/usab443","article-title":"HPV-related cancers: a growing threat to US military health and readiness","volume":"187","author":"Seay","year":"2022","journal-title":"Mil Med"},{"key":"2026031018415614500_usaf404-B22","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.7205\/MILMED-D-15-00477","article-title":"Improving human papillomavirus vaccinations in military women","volume":"181","author":"Wedel","year":"2016","journal-title":"Mil Med"},{"key":"2026031018415614500_usaf404-B23","first-page":"1","article-title":"Updates in human papillomavirus vaccination to improve medical readiness in active duty service members","author":"Hope","year":"2024","journal-title":"Mil Med"},{"key":"2026031018415614500_usaf404-B24","doi-asserted-by":"crossref","first-page":"e7345","DOI":"10.2196\/cancer.7345","article-title":"Health care providers\u2019 knowledge of HPV vaccination, barriers, and strategies in a state with low HPV vaccine receipt: mixed-methods study","volume":"3","author":"Warner","year":"2017","journal-title":"JMIR Cancer"},{"key":"2026031018415614500_usaf404-B25","doi-asserted-by":"crossref","first-page":"5281","DOI":"10.1002\/cam4.3192","article-title":"Reasons for not receiving the HPV vaccine among eligible adults: lack of knowledge and of provider recommendations contribute more than safety and insurance concerns","volume":"9","author":"Fokom Domgue","year":"2020","journal-title":"Cancer Med"},{"key":"2026031018415614500_usaf404-B26","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1093\/jnci\/djac034","article-title":"Cervical precancers and cancers attributed to HPV types by race and ethnicity: implications for vaccination, screening, and management","volume":"114","author":"Mix","year":"2022","journal-title":"JNCI"}],"container-title":["Military Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/milmed\/article-pdf\/191\/3-4\/e508\/64037807\/usaf404.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/milmed\/article-pdf\/191\/3-4\/e508\/64037807\/usaf404.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T22:42:05Z","timestamp":1773182525000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/milmed\/article\/191\/3-4\/e508\/8233757"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,8]]},"references-count":26,"journal-issue":{"issue":"3-4","published-online":{"date-parts":[[2025,8,8]]},"published-print":{"date-parts":[[2026,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/milmed\/usaf404","relation":{},"ISSN":["0026-4075","1930-613X"],"issn-type":[{"value":"0026-4075","type":"print"},{"value":"1930-613X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2025,8,8]]}}}